Aminoglycosides in Early Sepsis

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

1,900

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

May 31, 2033

Conditions
Sepsis
Interventions
DRUG

Gentamicin + narrow spectrum betalactam

Empirical therapy for suspected community-acquired sepsis with gentamicin + narrow spectrum betalactam (either one of penicillin, ampicillin, or cloxacillin)

DRUG

Cefotaxime

Empirical therapy for suspected community-acquired sepsis with cefotaxime

DRUG

Piperacillin-tazobactam

Empirical therapy for suspected community-acquired sepsis with piperacillin-tazobactam

Trial Locations (2)

1478

Akershus University Hospital, Lørenskog

0450

Oslo University Hospital Ullevål, Oslo

All Listed Sponsors
collaborator

Ullevaal University Hospital

OTHER

lead

University Hospital, Akershus

OTHER